Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17272 BIO-TECHNE CORPORATION (Exact name of registrant as specified in its charter) Minnesota 41-1427402 (State or other ...

Bio-Techne (TECH) reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks Consensus Estimate by 10.5%. The bottom line improved from the year-ago figure of 40 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The quarter's adjustments eliminated the impact of certain one-time items, including amortization of intangibles, amortization of Wilson Wolf intangible assets and acquired inventory and restructuring and restructuring-relat ...

Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Conference Call February 5, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President and Chief Executive Officer Jim Hippel - Executive Vice President and Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Dan Leonard - UBS Matt Larew - William Blair Catherine Schulte - Baird Dan Arias - Stifel Conor McNamara - RBC Patrick Donnelly - Citi Sung Ji Nam - Scotiabank Oper ...

Techne (TECH) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.53%. A quarter ago, it was expected that this maker of medical testing and diagnostic products would post earnings of $0.38 per share when it actually produced earnings of $0.42, delivering a surprise of 10.53%.Over the ...

Kelderman added, "The Bio-Techne growth vectors empower the discovery of novel biological insights, the development and manufacturing of advanced therapeutics and, enable precision diagnostics. Our portfolio plays a key role in the healthy aging of global populations. The combination of this unique portfolio with the talented Bio-Techne team positions the Company for continued differentiated financial performance." Exhibit 99.1 BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2025 RESULTS Minneapolis/February 5, 2 ...

MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools ...

MINNEAPOLIS, Feb. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024.Second Quarter FY2025 Highlights Second quarter organic revenue increased by 9% (9% reported) to $297.0 million. GAAP earnings per share (EPS) was $0.22 versus $0.17 one year ago. Delivered adjusted EPS of $0.42 compared to $0.40 one year ago. Improving biopharma end-market conditions combined with continued momentum of our cell and gene therapy ...

MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors.Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a ...

Bio-Techne Corporation (TECH) is set to release its second-quarter fiscal 2025 results on Feb. 5, before the opening bell.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 42 cents in the last reported quarter, which exceeded the Zacks Consensus Estimate by 10.53%. The company topped earnings estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.55 ...

Company Overview - CMBTECH is a diversified maritime group owning and operating over 160 seagoing vessels including crude oil tankers dry bulk vessels container ships chemical tankers offshore wind vessels tugboats and ferries [2] - The company also provides hydrogen and ammonia fuel to customers through its own production or third-party producers [2] - Headquartered in Antwerp Belgium with offices across Europe Asia the United States and Africa [3] - Listed on Euronext Brussels and the NYSE under the ticker symbol CMBT [3] Recent Transactions - CMBTECH sold several vessels generating a total capital gain of 4652 million USD [1] - Suezmax Cap Lara (2007 158826 dwt) sold for a capital gain of 1877 million USD with delivery scheduled for Q1 2025 [1] - VLCC Alsace (2012 299999 DWT) delivered to new owner with a capital gain of approximately 275 million USD to be booked in Q1 2025 [2] - Windcat 6 sold after 18 years of service generating a capital gain of 025 million USD with delivery expected by end of January 2025 [2] Upcoming Announcement - CMBTECH will announce its Q4 2024 results on 27 February 2025 [2]